Silver nanoparticles biosynthesized by secondary metabolites from Moringa oleifera stem and their antimicrobial properties
Abstract
Biological extracts have recently shown a great potential for rapid biosynthesis of silver nanoparticles (AgNPs) with antibacterial activity. AgNPs were synthetized by reduction effect of secondary metabolites produced by the Nigrospora sp. fungus, from Moringa oleifera stem as a reducing agent and silver nitrate (AgNO3) (1 mM) as salt precursor. The synthesis of nanoparticles (NPs) was monitored through analysis of the UV-Vis spectroscopy absorption in the 436 to 440 nm range indicating the presence of AgNPs in the colloidal aqueous solutions. Fourier transform infrared spectroscopy (FTIR) spectra were performed to identify the compounds responsible for the bio reduction of the Ag+. The morphology and sizes of AgNPs were characterized by scanning electron microscopy (SEM), energy dispersive of X-ray spectroscopy (EDS), dynamic light scattering (DLS), and colloid stability by zeta potential measurements. The NPs obtained were spherical in shape with size in the 3 to 70 nm range. Antibacterial activity was confirmed by evaluation of their effect against Escherichia coli, Klebsiella cloacae and Staphylococcus epidermidis. The proposed green synthesis of AgNPs from secondary metabolites produced by the Nigrospora sp. fungus from M. oleifera stem can be strongly recommended as a potential method for biomedical application.
Key words: Silver nanoparticles, secondary metabolites, green chemistry, antibacterial activity.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.